CAMBRIDGE, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate virtually in B. Riley Securities’ 3rd Annual Oncology Conference.
B. Riley Securities’ 3rd Annual Oncology Conference – Fireside Chat
Date: Wednesday, January 18, 2023
Time: 12:00 PM ET
A live webcast of the presentation will be available via the Investors section of the Company's website at www.vorbio.com. An archived replay of the webcast will also be available following the conference.
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Media & Investors
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.32 |
| Daily Change: | 0.20 17.86 |
| Daily Volume: | 3,350,815 |
| Market Cap: | US$90.640M |
December 27, 2024 November 07, 2024 September 05, 2024 | |
GreenPower Motor designs, builds and distributes a full suite of high-floor and low-floor all-electric medium and heavy-duty vehicles, including transit buses, school buses, shuttles, cargo van, and a cab and chassis...
CLICK TO LEARN MORE
Surf Air Mobility is a regional air mobility platform expanding the category of regional air travel to reinvent flying through the power of electrification. In an effort to substantially reduce the cost and environmental impact of...
CLICK TO LEARN MORE
